RAPID DOSE THERAPEUTICS CORP. Financials Rapid Dose Therapeutics Corp.
Equities
DOSE
CA75339A1012
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.255 CAD | +2.00% |
|
+24.39% | +54.55% |
| 03-25 | Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding | CI |
| 02-08 | Rapid Dose Therapeutics Corp. Appoints Angela O'Leary to the Board of Directors | CI |
Valuation
| Fiscal Period: February | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 62.35 | 26.59 | 16.94 | 26.45 | 9.322 |
| Enterprise Value (EV) 1 | 58.86 | 27.94 | 19.02 | 27.85 | 11.42 |
| P/E ratio | -4.57 x | -3.3 x | -7.11 x | -3.01 x | -2.44 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 261,958,511 x | 64,458,549 x | 15,100,230 x | 12,977,461 x |
| EV / Revenue | - | 275,244,468 x | 72,383,204 x | 15,898,275 x | 15,894,851 x |
| EV / EBITDA | -18.9 x | -3.82 x | -10.9 x | -7.28 x | -3.56 x |
| EV / FCF | 10,618,181 x | -18,207,757 x | -21,277,890 x | -17,945,919 x | 20,725,119 x |
| FCF Yield | 0% | -0% | -0% | -0% | 0% |
| Price to Book | 16.3 x | -180 x | -10.7 x | 105 x | -3.49 x |
| Nbr of stocks (in thousands) | 75,121 | 77,067 | 80,667 | 103,742 | 103,574 |
| Reference price 2 | 0.8300 | 0.3450 | 0.2100 | 0.2550 | 0.0900 |
| Announcement Date | 19-05-29 | 20-11-16 | 21-08-24 | 23-01-27 | 23-06-28 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: February | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 0.1015 | 0.2628 | 1.752 | 0.7183 |
| EBITDA 1 | -1.801 | -3.119 | -7.31 | -1.74 | -3.825 | -3.205 |
| EBIT 1 | -1.802 | -3.275 | -7.505 | -2.127 | -4.302 | -3.544 |
| Operating Margin | - | - | -7,394.53% | -809.36% | -245.55% | -493.36% |
| Earnings before Tax (EBT) 1 | -1.802 | -11.4 | -7.965 | -2.298 | -8.487 | -3.81 |
| Net income 1 | -1.802 | -11.4 | -7.965 | -2.298 | -8.487 | -3.81 |
| Net margin | - | - | -7,847.07% | -874.28% | -484.47% | -530.42% |
| EPS 2 | -0.0528 | -0.1816 | -0.1047 | -0.0295 | -0.0847 | -0.0368 |
| Free Cash Flow | - | 5.543 | -1.534 | -0.894 | -1.552 | 0.5509 |
| FCF margin | - | - | -1,511.69% | -340.18% | -88.59% | 76.69% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 18-07-13 | 19-05-29 | 20-11-16 | 21-08-24 | 23-01-27 | 23-06-28 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: February | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 1.35 | 2.08 | 1.4 | 2.1 |
| Net Cash position 1 | 0.33 | 3.49 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.1845 x | -1.197 x | -0.3656 x | -0.6539 x |
| Free Cash Flow | - | 5.54 | -1.53 | -0.89 | -1.55 | 0.55 |
| ROE (net income / shareholders' equity) | - | -516% | -433% | 266% | 2,025% | 315% |
| ROA (Net income/ Total Assets) | - | -62.9% | -93.1% | -32.7% | -77.9% | -83.3% |
| Assets 1 | - | 18.13 | 8.552 | 7.018 | 10.89 | 4.571 |
| Book Value Per Share 2 | 0.0100 | 0.0500 | -0 | -0.0200 | 0 | -0.0300 |
| Cash Flow per Share 2 | 0.0100 | 0.0200 | 0 | 0 | 0 | 0 |
| Capex 1 | 0.21 | 1.67 | 1.22 | 0.01 | 0.04 | - |
| Capex / Sales | - | - | 1,205.39% | 3.47% | 2.3% | - |
| Announcement Date | 18-07-13 | 19-05-29 | 20-11-16 | 21-08-24 | 23-01-27 | 23-06-28 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +54.55% | 22.5M | |
| -10.84% | 187M |
- Stock Market
- Equities
- DOSE Stock
- Financials Rapid Dose Therapeutics Corp.
